Forbion has released its 2024 Impact & ESG Report, prepared under the leadership of Head of Impact and ESG, Silva Dezelan, PhD. The report outlines a year of significant advancement toward our mission of improving health outcomes and contributing to planetary well-being.
2024 Impact Report Highlights
-
Patient reach: More than 1.45 million patients were impacted by approved products originating from former portfolio companies.
-
Innovation at scale: 71 drug programs in the clinic and 134 active programs across the portfolio, addressing high unmet medical needs from oncology to rare genetic disorders.
-
Clinical progress: Multiple portfolio companies achieved pivotal milestones, including positive Phase II and Phase III trial results in cardiovascular disease, oncology, and rare lysosomal disorders.
-
Economic growth: Over 2,230 jobs supported and more than 400 new hires across Forbion funds.
-
Planetary health: Launch of the BioEconomy fund, investing in biotechnology solutions that reduce emissions and support sustainable food and materials systems.
These results demonstrate how Forbion-backed companies are advancing breakthrough therapies while integrating responsible business practices and rigorous ESG standards. To contact our Impact team, please click here.
